What is the recommended dosing schedule for metaxalone in adults, including adjustments for elderly or hepatic impairment?

Metaxalone Dosing in Adults

The standard adult dose of metaxalone is 800 mg (two 400 mg tablets) taken 3 to 4 times daily, with no dosage adjustments required for elderly patients or those with hepatic impairment—though the drug should be avoided entirely in patients with significant hepatic dysfunction. 1

Standard Adult Dosing

• Recommended dose: 800 mg orally 3 to 4 times daily 1
• Available formulations: 400 mg and 800 mg tablets 1
• Peak plasma concentration: Occurs approximately 3 hours after a 400 mg dose under fasted conditions 1
• Half-life: 8–9 hours under standard conditions 1

Food Effects on Absorption

• Taking metaxalone with food significantly increases drug exposure: A high-fat meal increases Cmax by 177–194% and AUC by 115–146% compared to fasted conditions 1
• Time to peak concentration is delayed: Tmax increases from 3.0–3.3 hours (fasted) to 4.3–4.9 hours (fed) 1
• Clinical implication: While the FDA label does not mandate administration with food, patients should be counseled that taking metaxalone with meals will substantially increase drug exposure and may enhance both therapeutic and adverse effects 1

Elderly Patients

• No routine dose reduction is required for elderly patients 1
• Age-related pharmacokinetic changes: Under fasted conditions, bioavailability increases with age—elderly patients (mean age 71.5 years) had higher Cmax (1531 ng/mL) and AUC (24192 ng·h/mL) compared to younger adults (Cmax 1816 ng/mL, AUC 14531 ng/mL at age 25.6 years) 1
• However, the perioperative consensus recommends holding metaxalone on the day of surgery due to CNS depressant effects 2

Hepatic Impairment

• Metaxalone is contraindicated in patients with significant hepatic dysfunction 2, 1
• Rationale: Metaxalone is extensively metabolized by hepatic CYP450 enzymes (primarily CYP1A2, CYP2D6, CYP2E1, and CYP3A4), and impaired hepatic function has not been studied—no dosing adjustments are available 1
• The drug has been associated with drug-induced hemolytic anemia and other anemias, further supporting avoidance in hepatic disease 2

Renal Impairment

• The impact of renal disease on metaxalone pharmacokinetics has not been determined 1
• Use with caution in renal impairment, though no specific dosage adjustments are provided in the FDA label 1

Gender Differences

• Females have significantly higher metaxalone exposure than males: Cmax is 2115 ng/mL in females versus 1335 ng/mL in males, and AUC is 17,884 ng·h/mL versus 10,328 ng·h/mL 1
• Mean half-life is longer in females: 11.1 hours versus 7.6 hours in males 1
• No formal dose adjustment is recommended, but clinicians should be aware of increased risk of adverse effects in female patients 1

Duration of Therapy and Efficacy Considerations

• Evidence does not support routine use of metaxalone for acute low back pain: Multiple randomized trials found no benefit over placebo when added to NSAIDs, with similar functional improvement (RMDQ score improvement ~10 points) in both groups 3, 4
• Limit duration to short-term use only, as prolonged therapy has not been studied and the drug lacks proven efficacy beyond placebo in controlled trials 3, 4

Important Safety Considerations

CNS and Perioperative Management

• Hold metaxalone on the day of surgery due to CNS depressant effects including drowsiness, dizziness, and irritability 2
• Common adverse effects in overdose include: Drowsiness (27.9%), tachycardia (6.6%), agitation (6.6%), nausea (4.9%), dizziness (4.9%), slurred speech (4.9%), and tremor (4.9%) 5

Serotonin Syndrome Risk

• Metaxalone at toxic concentrations (31–61 mcg/mL) inhibits monoamine oxidase A (MAO-A), which can precipitate serotonin syndrome when combined with SSRIs or other serotonergic drugs 6, 7
• Therapeutic peak plasma concentrations average only 0.9 mcg/mL after a 400 mg dose, so this risk is primarily relevant in overdose scenarios 7
• Clinicians should counsel patients taking SSRIs or SNRIs to avoid exceeding prescribed doses and to seek immediate care if symptoms of serotonin toxicity develop (hyperthermia, rigidity, myoclonus, hyperreflexia, altered mental status) 6, 7

Overdose Management

• Ingestions >2400 mg are associated with more serious medical outcomes and require management at a healthcare facility 5
• Moderate toxicity occurred in 20.5% of ingestions >2400 mg versus 13.6% of ingestions ≤2400 mg 5

Common Pitfalls to Avoid

• Do not prescribe metaxalone to patients with hepatic impairment, as metabolism is entirely hepatic and no dosing guidance exists for this population 2, 1
• Do not combine metaxalone with other CNS depressants or serotonergic medications without careful monitoring, particularly in patients taking SSRIs or SNRIs 6, 7
• Do not expect superior efficacy compared to NSAIDs alone for acute low back pain, as controlled trials show no added benefit 3, 4
• Do not continue metaxalone on the day of elective surgery, as perioperative guidelines recommend holding all skeletal muscle relaxants including metaxalone 2